1334719-95-7

Usage

Uses

Used in Pharmaceutical Industry:
Q203 is used as an anti-tubercular agent for its ability to inhibit the growth of both drug-sensitive and drug-resistant strains of M. tuberculosis. It demonstrates synergistic effects when combined with other anti-tubercular agents, enhancing the overall efficacy of treatment.
Used in Clinical Trials:
Q203 is used in clinical trials to investigate its potential as a treatment for drug-resistant tuberculosis. The promising results from these trials highlight its potential as a novel and effective anti-tubercular agent capable of addressing the growing problem of drug resistance in tuberculosis treatment.

Upstream product

• 1334721-53-7 ethyl 6-chloro-2-ethylimidazo[1,2-a]pyridine-3-carboxylate 
• 4949-44-4 ethyl propanoylacetate 
• 1194-02-1 4-fluorobenzonitrile 
• 87943-99-5 ethyl 2-bromo-3-oxopentanoate 
• 1613627-57-8 4-(4-(4-(trifluoromethoxy)phenyl)piperidine-1-yl)benzonitrile 
• 180160-91-2 4-(4-(trifluoromethoxy)phenyl)piperidine 
• 407-14-7 1-bromo-4-(trifluoromethoxy)benzene 
• 623-00-7 4-bromobenzenecarbonitrile 
• 169222-42-8 (4-(trifluoromethoxy)-phenyl)magnesium bromide 
• 459819-54-6 4-(4-(trifluoromethoxy)phenyl)piperidine-1-formic acid tert-butyl ester 

Relevant academic research and scientific papers

Cobalt-Catalyzed Electrophilic Amination of Aryl- and Heteroarylzinc Pivalates with N-Hydroxylamine Benzoates

Aryl- and heteroarylzinc pivalates can be aminated with O-benzoylhydroxylamines at 25 °C within 2–4 h in the presence of 2.5–5.0 % CoCl2?2 LiCl to furnish the corresponding tertiary arylated or heteroarylated amines in good yields. This electrophilic amination also provides access to diarylamines and aryl(heteroaryl)amines. A new tuberculosis drug candidate (Q203) was prepared in six steps and 56 % overall yield by using this cobalt-catalyzed amination as the key step.

Lead optimization of a novel series of imidazo[1,2-a]pyridine amides leading to a clinical candidate (Q203) as a multi- and extensively-drug- resistant anti-tuberculosis agent

A critical unmet clinical need to combat the global tuberculosis epidemic is the development of potent agents capable of reducing the time of multi-drug-resistant (MDR) and extensively-drug-resistant (XDR) tuberculosis therapy. In this paper, we report on the optimization of imidazo[1,2-a]pyridine amide (IPA) lead compound 1, which led to the design and synthesis of Q203 (50). We found that the amide linker with IPA core is very important for activity against Mycobacterium tuberculosis H37Rv. Linearity and lipophilicity of the amine part in the IPA series play a critical role in improving in vitro and in vivo efficacy and pharmacokinetic profile. The optimized IPAs 49 and 50 showed not only excellent oral bioavailability (80.2% and 90.7%, respectively) with high exposure of the area under curve (AUC) but also displayed significant colony-forming unit (CFU) reduction (1.52 and 3.13 log10 reduction at 10 mg/kg dosing level, respectively) in mouse lung.

ANTI-INFECTIVE COMPOUNDS

The present invention relates to small molecule compounds and their use in the treatment of bacterial infections, in particular Tuberculosis.